Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

NCT02317159 is registered in ClinicalTrials.gov with Cttq as lead sponsor.

NCT NCT02317159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02317159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Lead sponsor
Cttq
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2015
Completion date
July 31, 2017
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia